{"name":"Elpiscience (Suzhou) Biopharma, Ltd.","slug":"elpiscience-suzhou-biopharma-ltd","ticker":"","exchange":"","domain":"","description":"Elpiscience (Suzhou) Biopharma, Ltd. is a biotechnology company focused on developing innovative therapies in oncology and immunology. The company has two drugs in clinical development, ES104 in Phase 1 and ES014 in Phase 2.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ES014","genericName":"ES014","slug":"es014","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"ES014","genericName":"ES014","slug":"es014","phase":"phase_2","mechanism":"ES014 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0IyRmpWZzhoSnhlMVFEdVdtRzM2TjRtN0FfSXp5YjBSMHJVcGZwNlJxR09OODhWQWhIM3NRcV9pdEczQUhiaEs1aXpXYVlRWFlWb1k5QVVfd0t5bmQxRmVGblpDZVM4SmRtN2taaExmRU9KN3BmLU95bVRRM1V4aWtYaEZQVGpZNzRsOEVrSTdVc2FiVTFDcDJhb19DczA5M2IzM0FR?oc=5","date":"2025-12-09","type":"pipeline","source":"BioWorld News","summary":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025 - BioWorld News","headline":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOOEloNzBMUVo2VDlxYlpXM2NsZWh0Zmgyb0dZc2dWaXJNUm9adUtqNmdKaWVIWGZnbFJrdWE3bHhZeFlMYkZfc1lpb0N3TXVRQXExTUJaQUZFWFdOTlJOQjhsYkpBM2piWEhJazBwRlpKaUs2YzN0LWFyLW1OUFFSREpRM1IzbklTVkU0Y2RSUHB6TTdnNG0zUGZMVHNnWHhhVlZMRXdwNklETXVwY0tSQ2J3am82VmpRQ2dRX2d6WHh0cGg0TGR4ZEVTb1JGYXNKX2I4S0xBcDFsSWRla1JmaXEzdHdGTVlPcXVXSXJWekRLdUNzQk1VS1YzMVVQVjE2eFZLQjB6Y2JhWFZTbWZXN2l5OFRlOEYxZ3o2ZHFHMkJuMUdZM0ltX3NJRTJSNWVZTWUybThENGFlSWh4ZWc?oc=5","date":"2025-04-23","type":"pipeline","source":"PR Newswire","summary":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire","headline":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQRmNCT3RSOFc2ZGVjb3NpTWo4QVpHMmhBTm52VWFlMTZDRlc3NFFlc1RiUDZlWnlIYnliTk54c1BkWEo0c1RDUUdxVG1ma2NZd0ZPM1hrZEc5ejV4UUtEaHVIc1RvX28tQVllVU9kNl83UzZVV21oYXdSMmw4T21uakhuRVkzbENEejRJbVE0TVY4a3d2UGpRaXhkY2pzTHJKbUJCOVV2MTJFQXlVVFdpaHRWaWF4TFlPQWs0Nmx2OU4yYmtDSVR6VDFMdjROLWx1YWF0eGtyelhFRWNUMmJqR3Z4VHZOejA3dlhxS09uVWU1eHhzTkNlOEtoSDJSQU5sWWIwMVJFUQ?oc=5","date":"2023-12-28","type":"deal","source":"PR Newswire","summary":"Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager - PR Newswire","headline":"Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}